Wedbush analyst Liana Moussatos reiterated an Outperform rating and $123 price target on Pacira Pharmaceuticals (NASDAQ: PCRX) saying November Symphony ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE